Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal.
Trends Biotechnol. 2012 Jun;30(6):350-9. doi: 10.1016/j.tibtech.2012.03.003. Epub 2012 Apr 26.
Human pluripotent stem cells (hPSCs), including embryonic and induced pluripotent stem cells, constitute an extremely attractive tool for cell therapy. However, flexible platforms for the large-scale production and storage of hPSCs in tightly controlled conditions are necessary to deliver high-quality cells in relevant quantities to satisfy clinical demands. Here we discuss the main principles for the bioprocessing of hPSCs, highlighting the impact of environmental factors, novel 3D culturing approaches and integrated bioreactor strategies for controlling hPSC culture outcome. Knowledge on hPSC bioprocessing accumulated during recent years provides important insights for the establishment of more robust production platforms and should potentiate the implementation of novel hPSC-based therapies.
人多能干细胞(hPSCs),包括胚胎干细胞和诱导多能干细胞,是细胞治疗的一种极具吸引力的工具。然而,为了在严格控制的条件下大规模生产和储存 hPSCs,需要灵活的平台,以提供高质量的细胞,并满足相关数量的临床需求。在这里,我们讨论了 hPSCs 的生物处理的主要原则,强调了环境因素的影响、新型 3D 培养方法以及用于控制 hPSC 培养结果的集成生物反应器策略。近年来在 hPSC 生物处理方面积累的知识为建立更强大的生产平台提供了重要的见解,并应该促进新型基于 hPSC 的治疗方法的实施。